|Application ||WB, IHC-P|
|Calculated MW||350687 Da|
|Purification||Antisera to ATM were raised by repeated immunisation of rabbits with highly purified antigen.|
|Immunogen||Recombinant human ATM fragment (amino acids 1980-2338).|
|Shelf Life||18 months from date of despatch.|
|Other Names||Serine-protein kinase ATM, 22.214.171.124, Ataxia telangiectasia mutated, A-T mutated, ATM|
|Target/Specificity||ABD11294 recognises the human ATM protein, a 350kD polypeptide that is the product of the ATM gene. The ATM gene is defective in Ataxia telangiectasia.ATM protein is expressed within the nucleus of all normal cells and is thought to be important in detection of DNA damage.|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-ATM (aa1980-2338) Antibody (Serum) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Lakin, N. D. et al. (1996) Analysis of the ATM protein in wild-type and ataxia telangiectasia cells.Oncogene 13: 2707-2716. 2. Aggarwal, P. et al. (2007) Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication.Genes Dev. 21: 2908-2922. 3. Condon, L.T. et al. (2002) Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance.Int J Cancer. 100: 472-5. 4. Ejima, Y. et al. (2000) Aberrant splicing of the ATM gene associated with shortening of the intronic mononucleotide tract in human colon tumor cell lines: a novel mutation target of microsatellite instability.Int J Cancer. 86: 262-8. 5. Angèle, S. et al. (2003) Phenotypic cellular characterization of an ataxia telangiectasia patient carrying a causal homozygous missense mutation.Hum Mutat. 21: 169-70. 6. Angèle, S. et al. (2003) ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity.Cancer Res. 63: 8717-25. 7. Fernet, M. et al. (2004) Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers.Br J Cancer. 90: 866-73.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.